Literature DB >> 14625552

Mitochondrial dysfunction and apoptosis in myopathic mice with collagen VI deficiency.

William A Irwin1, Natascha Bergamin, Patrizia Sabatelli, Carlo Reggiani, Aram Megighian, Luciano Merlini, Paola Braghetta, Marta Columbaro, Dino Volpin, Giorgio M Bressan, Paolo Bernardi, Paolo Bonaldo.   

Abstract

Collagen VI is an extracellular matrix protein that forms a microfilamentous network in skeletal muscles and other organs. Inherited mutations in genes encoding collagen VI in humans cause two muscle diseases, Bethlem myopathy and Ullrich congenital muscular dystrophy. We previously generated collagen VI-deficient (Col6a1-/-) mice and showed that they have a muscle phenotype that strongly resembles Bethlem myopathy. The pathophysiological defects and mechanisms leading to the myopathic disorder were not known. Here we show that Col6a1-/- muscles have a loss of contractile strength associated with ultrastructural alterations of sarcoplasmic reticulum (SR) and mitochondria and spontaneous apoptosis. We found a latent mitochondrial dysfunction in myofibers of Col6a1-/- mice on incubation with the selective F1F(O)-ATPase inhibitor oligomycin, which caused mitochondrial depolarization, Ca2+ deregulation and increased apoptosis. These defects were reversible, as they could be normalized by plating Col6a1-/- myofibers on collagen VI or by addition of cyclosporin A (CsA), the inhibitor of mitochondrial permeability transition pore (PTP). Treatment of Col6a1-/- mice with CsA rescued the muscle ultrastructural defects and markedly decreased the number of apoptotic nuclei in vivo. These findings indicate that collagen VI myopathies have an unexpected mitochondrial pathogenesis that could be exploited for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14625552     DOI: 10.1038/ng1270

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  197 in total

Review 1.  Animal models of muscular dystrophy.

Authors:  Rainer Ng; Glen B Banks; John K Hall; Lindsey A Muir; Julian N Ramos; Jacqueline Wicki; Guy L Odom; Patryk Konieczny; Jane Seto; Joel R Chamberlain; Jeffrey S Chamberlain
Journal:  Prog Mol Biol Transl Sci       Date:  2012       Impact factor: 3.622

Review 2.  Congenital muscular dystrophies: toward molecular therapeutic interventions.

Authors:  James Collins; Carsten G Bönnemann
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

3.  Expression of COL6A1 predicts prognosis in cervical cancer patients.

Authors:  Teng Hou; Chongjie Tong; Gallina Kazobinka; Weijing Zhang; Xin Huang; Yongwen Huang; Yanna Zhang
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

4.  Modulation of F0F1-ATP synthase activity by cyclophilin D regulates matrix adenine nucleotide levels.

Authors:  Christos Chinopoulos; Csaba Konràd; Gergely Kiss; Eugeniy Metelkin; Beata Töröcsik; Steven F Zhang; Anatoly A Starkov
Journal:  FEBS J       Date:  2011-02-23       Impact factor: 5.542

5.  Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy.

Authors:  Mahasweta Girgenrath; Janice A Dominov; Christine A Kostek; Jeffrey Boone Miller
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

6.  Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts.

Authors:  Nina Kaludercic; Andrea Carpi; Takahiro Nagayama; Vidhya Sivakumaran; Guangshuo Zhu; Edwin W Lai; Djahida Bedja; Agnese De Mario; Kevin Chen; Kathleen L Gabrielson; Merry L Lindsey; Karel Pacak; Eiki Takimoto; Jean C Shih; David A Kass; Fabio Di Lisa; Nazareno Paolocci
Journal:  Antioxid Redox Signal       Date:  2013-05-22       Impact factor: 8.401

Review 7.  Mitochondrial dysfunction and defective autophagy in the pathogenesis of collagen VI muscular dystrophies.

Authors:  Paolo Bernardi; Paolo Bonaldo
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-05-01       Impact factor: 10.005

Review 8.  Recent advances using zebrafish animal models for muscle disease drug discovery.

Authors:  Lisa Maves
Journal:  Expert Opin Drug Discov       Date:  2014-06-14       Impact factor: 6.098

9.  The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-/- myopathic mice.

Authors:  T Tiepolo; A Angelin; E Palma; P Sabatelli; L Merlini; L Nicolosi; F Finetti; P Braghetta; G Vuagniaux; J-M Dumont; C T Baldari; P Bonaldo; P Bernardi
Journal:  Br J Pharmacol       Date:  2009-06-10       Impact factor: 8.739

10.  Peroxisome proliferator-activated receptor γ coactivator1- gene α transfer restores mitochondrial biomass and improves mitochondrial calcium handling in post-necrotic mdx mouse skeletal muscle.

Authors:  Richard Godin; Frederic Daussin; Stefan Matecki; Tong Li; Basil J Petrof; Yan Burelle
Journal:  J Physiol       Date:  2012-08-20       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.